Apollo in talks for J&J orthopedics unit
Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 14, 2026
The reported talks signal continued private equity appetite for large healthcare assets, which could support valuations across medical-device and healthcare services peers. For J&J, a sale or spinoff near $20 billion would sharpen its focus on higher-growth segments, while for Apollo it would be its largest healthcare deal to date, adding a large recurring-demand device business.
Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, Johnson & Johnson — DePuy Synthes, in a deal that could value the business at close to $20 billion, according to Bloomberg News. The discussions are non-binding and an agreement could be reached within several weeks, though sources caution the talks could end without a deal or another bidder could emerge. Several private equity firms have reportedly shown interest in the unit. Johnson & Johnson has also retained the option of spinning off Johnson & Johnson — DePuy Synthes as a publicly traded company, a path it announced in 2025 with a target of completing a separation by mid-2027. Johnson & Johnson — DePuy Synthes makes hip, knee and shoulder implants and surgical instruments, generated $9.3 billion in sales in 2025, and would become the world's largest standalone orthopedics company if separated. The unit was created through J&J's roughly $21 billion takeover of Johnson & Johnson — DePuy Synthes in 2012, combined with its earlier DePuy business acquired from Roche. The potential deal reflects growing private equity interest in healthcare, following American Industrial Partners' $1.27 billion acquisition of Avanos Medical and the agreement by Blackstone and TPG to acquire Hologic for over $18 billion. Bloomberg L.P. — Bloomberg L.P. has estimated Johnson & Johnson — DePuy Synthes could be worth about $28 billion including debt, above the valuation currently discussed. J&J shares were little changed at $265.58, while Apollo gained 0.8% to $128.98.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard